These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 18533276)

  • 1. A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro.
    Wang X; Xu W; Tong D; Ni J; Gao H; Wang Y; Chu Y; Li P; Yang X; Xiong S
    Immunol Lett; 2008 Aug; 119(1-2):71-7. PubMed ID: 18533276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice.
    Hu H; Lu X; Tao L; Bai B; Zhang Z; Chen Y; Zheng F; Chen J; Chen Z; Wang H
    Clin Vaccine Immunol; 2007 Jul; 14(7):894-901. PubMed ID: 17494640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.
    Woo PC; Lau SK; Tsoi HW; Chen ZW; Wong BH; Zhang L; Chan JK; Wong LP; He W; Ma C; Chan KH; Ho DD; Yuen KY
    Vaccine; 2005 Oct; 23(42):4959-68. PubMed ID: 15993989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses.
    Huang J; Cao Y; Du J; Bu X; Ma R; Wu C
    Vaccine; 2007 Sep; 25(39-40):6981-91. PubMed ID: 17709158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
    Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G
    Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterologous viral RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS.
    Callendret B; Lorin V; Charneau P; Marianneau P; Contamin H; Betton JM; van der Werf S; Escriou N
    Virology; 2007 Jul; 363(2):288-302. PubMed ID: 17331558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies.
    Faber M; Lamirande EW; Roberts A; Rice AB; Koprowski H; Dietzschold B; Schnell MJ
    J Gen Virol; 2005 May; 86(Pt 5):1435-1440. PubMed ID: 15831955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.
    He Y; Lu H; Siddiqui P; Zhou Y; Jiang S
    J Immunol; 2005 Apr; 174(8):4908-15. PubMed ID: 15814718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
    Buchholz UJ; Bukreyev A; Yang L; Lamirande EW; Murphy BR; Subbarao K; Collins PL
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9804-9. PubMed ID: 15210961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection.
    Channappanavar R; Fett C; Zhao J; Meyerholz DK; Perlman S
    J Virol; 2014 Oct; 88(19):11034-44. PubMed ID: 25056892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
    See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
    J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV spike proteins expressed by the vaccinia virus Tiantan strain: secreted sq protein induces robust neutralization antibody in mice.
    Yan K; Tan W; Wang H; Wang Y; Zhang X; Li Y; Ruan L
    Viral Immunol; 2009 Feb; 22(1):57-66. PubMed ID: 19210229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.
    ter Meulen J; van den Brink EN; Poon LL; Marissen WE; Leung CS; Cox F; Cheung CY; Bakker AQ; Bogaards JA; van Deventer E; Preiser W; Doerr HW; Chow VT; de Kruif J; Peiris JS; Goudsmit J
    PLoS Med; 2006 Jul; 3(7):e237. PubMed ID: 16796401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
    He Y; Zhu Q; Liu S; Zhou Y; Yang B; Li J; Jiang S
    Virology; 2005 Mar; 334(1):74-82. PubMed ID: 15749124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of antibody responses against SARS coronaviral nucleocapsid or spike proteins by immunoblotting or ELISA.
    Huang LR; Chiu CM; Yeh SH; Huang WH; Hsueh PR; Yang WZ; Yang JY; Su IJ; Chang SC; Chen PJ
    J Med Virol; 2004 Jul; 73(3):338-46. PubMed ID: 15170626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus.
    Ba L; Yi CE; Zhang L; Ho DD; Chen Z
    Appl Microbiol Biotechnol; 2007 Oct; 76(5):1131-6. PubMed ID: 17581748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.
    Du L; Zhao G; Chan CC; Sun S; Chen M; Liu Z; Guo H; He Y; Zhou Y; Zheng BJ; Jiang S
    Virology; 2009 Oct; 393(1):144-50. PubMed ID: 19683779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a B-cell antigenic epitope at the N-terminus of SARS-CoV M protein and characterization of monoclonal antibody against the protein.
    Qian C; Qin D; Tang Q; Zeng Y; Tang G; Lu C
    Virus Genes; 2006 Oct; 33(2):147-56. PubMed ID: 16972028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.
    Du L; Zhao G; He Y; Guo Y; Zheng BJ; Jiang S; Zhou Y
    Vaccine; 2007 Apr; 25(15):2832-8. PubMed ID: 17092615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity.
    Liang MF; Du RL; Liu JZ; Li C; Zhang QF; Han LL; Yu JS; Duan SM; Wang XF; Wu KX; Xiong ZH; Jin Q; Li DX
    Biomed Environ Sci; 2005 Dec; 18(6):363-74. PubMed ID: 16544518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.